Government Contract Win May Improve Investor Sentiment For SIGA Tech After Disappointing Trial Data: Analyst
Government Contract Win May Improve Investor Sentiment For SIGA Tech After Disappointing Trial Data: Analyst
On Wednesday, SIGA Technologies, Inc. (NASDAQ:SIGA) announced a new contract with the U.S. Department of Defense (DOD) to procure approximately $9 million of TPOXX.
周三，SIGA Technologies, Inc. (纳斯达克: SIGA) 宣布与美国国防部（DOD）签署了一份新合同，采购约900万美元的TPOXX。
This award is comprised primarily of oral TPOXX, with a small amount of intravenous (IV) TPOXX, and represents the third procurement contract award from the DOD over the past three years.
这项奖励主要包括口服TPOXX，少量静脉注射（IV）TPOXX，代表DOD在过去三年内的第三份采购合同奖励。
The company also received approximately $27 million to develop the post-exposure Prophylaxis indication for oral TPOXX.
公司还获得了约2700万美元用于开发口服TPOXX的暴露后预防适应症。
Also Read: Mpox Variant Sparks Global Concern As Europe, China Ramp Up Screening.
另请参阅：M阴毒变种引发全球关注，欧洲、中国加强筛查。
Inclusive of this award, SIGA currently has approximately $154 million of outstanding oral and IV TPOXX orders, more than 85% of which were generated within the past three months.
包括此次奖励在内，SIGA目前有约1.54亿美元的口服和IV TPOXX订单未完成，其中超过85%是在过去三个月内产生的。
Edison report adds that SIGA continues to advance its growth strategy, with recent contract wins from BARDA and the Department of Defense significantly boosting its order book.
Edison报告还指出，SIGA继续推进其增长策略，最近从BARDA和国防部获得的合同奖励显著提高了其60档摆盘。
The company is set to deliver IV TPOXX under orders from July 2023 ($25 million), and August 2022 ($8.4 million, of which $17.8 million from a $26 million order was already delivered in the first half of 2024).
该公司拟在2023年7月（2500万美元）和2022年8月（840万美元，其中2600万美元订单中的1780万美元已在2024年上半年交付）交付IV TPOXX。
These are part of approximately $155 million in outstanding TPOXX (oral and IV) orders.
这些是约1.55亿美元未完成的TPOXX（口服和IV）订单的一部分。
SIGA anticipates delivering the remaining August 2022 IV TPOXX order and 80% of the BARDA oral TPOXX order in the second half of 2024.
SIGA预计在2024年下半年交付剩余的2022年8月IV TPOXX订单和80%的BARDA口服TPOXX订单。
While delivery timeline details are yet to be disclosed, Edison Group's report notes that new DoD order to start at least being partially serviced in fiscal year 2025.
尽管交付时间表尚未公布，Edison Group的报告指出，新的国防部订单将在2025财年部分启动服务。
Recently, the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) announced topline results from a preliminary analysis of the PALM 007 trial of tecovirimat for mpox.
最近，美国国家卫生研究院过敏与传染病研究所(NIAID)公布了对tecovirimat治疗m病po脊髓膜炎(PALm 007试验)初步分析的最终结果。
NIAID reported that the study did not meet its primary endpoint of a statistically significant improvement in time to lesion resolution within 28 days post-randomization for patients in the Democratic Republic of the Congo with mpox who were administered SIGA's tecovirimat versus placebo, weighing on the share price.
NIAID报告称，在刚果民主共和国mpo脊髓膜炎患者中，SIGA的tecovirimat与安慰剂相比，28天随机治疗后，疗程内病变恢复时间没有达到统计学显著改善，对股价造成了压力。
Edison analysts expect an improvement in investor sentiment with the recent DoD contract win.
Edison分析师预计，最近的国防部合同获得将改善投资者情绪。
"We maintain that mpox continues to be an opportunity for SIGA on the heels of the WHO declaration of a global health emergency," the analysts added.
分析师补充道：“我们认为，在世界卫生组织宣布全球卫生紧急状态之后，mpo脊髓膜炎仍然是SIGA的机会。”
Price Action: SIGA stock is up 4.07% at $9.72 at the last check on Friday.
SIGA股票在上周五最后一次查询时上涨了4.07%，报价为9.72美元。
- Europe Approves Moderna's RSV Vaccine For Adults 60 And Over.
- 欧洲批准Moderna的RSV疫苗供60岁以上成年人使用。
